Is HKEX ready to return to biotech business? InnoCare tests waters with hopes to fetch $257M in IPO
The Covid-19 outbreak may have forced InnoCare Pharma to postpone investor meetings ahead of its public debut on the Hong Kong Stock Exchange, but it hasn’t stopped the biotech from carrying on with an IPO that could bring in $257 million (HKD1.993 billion) at the midpoint.
The real test begins today. Investors now have five days to file their share applications before the final expected price is determined next Monday and announced next Friday. Trading is expected to commence the week after.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.